GIC makes another bet on Chinese pharma

Singapore’s state fund leads $85 million funding for Harbour BioMed, marking its third investment in the Chinese pharmaceutical space in four months.

GIC makes another bet on Chinese pharma

Singapore’s sovereign wealth fund GIC Private has led an $85 million financing round for Chinese pharmaceutical startup Harbour BioMed, extending its long streak of private equity investment in China so far this year.

GIC Private was joined by China Life Private Equity Investment and Vertex Ventures in the series B round of financing, the young pharmaceutical startup said in a statement on Monday.

Taiwanese technology company AdvanTech and Legend...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: gic | harbour biomed | private equity | healthcare | china

Print Edition

FinanceAsia Print Edition

EVENTS